中文摘要：

目的探讨抗CD22单抗（CD22McAb）对免疫性扩张型心肌病（DCM）早期治疗效果。方法Balb／c小鼠随机分为心肌病组、早期治疗组、对照组，采取流式细胞术检测小鼠B细胞表面CD22分子表达的变化，ELISA法检测小鼠血清抗ANT抗体动态变化，观察小鼠心肌组织的病理改变。结果与对照组比较，早期治疗组与心肌病组小鼠B细胞表面CD22分子表达均明显增高，血清抗ANT抗体检测均为阳性。早期治疗组与心肌病组相比，CD22，McAb治疗免疫性DCM小鼠B细胞表面的CD22表达在第30天明显下降，抗体水平在第1个月末有短暂降低，病理及超微结构检查示心肌损害相对较轻。结论应用CD22McAb对免疫性DCM小鼠进行早期干预，可在一定程度上抑制B细胞生成抗ANT抗体，延缓免疫性DCM的发生发展。

英文摘要：

Objective To explore the effects of treatment with anti- CD22 monoclonal anti.body on mice with immune dilated cardiomyopathy. Methods Fifty four male Balb/c mice were divided into three equal groups： cardiomyopathy group： immunized with the adenine neucleotide translocator （ANT） peptides; early-treated group： injected with CD22 McAb 160 ug/kg on the 1st, 3rd, 5th day after the first immunization; control group： dealed with the same solution as those of cardiomyopathy group without the peptides. Expression of CD22 on B cells were tested with FC. The levels of anti- ANT antibodies in serum were monitored with ELISA. The myocardial pathological changes were examined with light and electron microscopes. Results Compared with the control group, the expression of CD22 on B cell was increased significantly both in early-treated group and cardiomyopathy group, with ANT antibodies being found. The expression of CD22 was less obvious and the levels of anti-ANT antibodies decreased transiently on the 1 st month with slight myocardial damage in the former group, compared with the latter. In the control group, antibody was negative and no change was found in expression of CD22 and myecarcial pathology. Condusion Given early to mice with immune dilated cardiomyopathy, CD22 McAb could inhibit B cells to produce the anti-ANT antibody and delay the development of immene dilated cardiomyopathy in mice.